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The Effects of FK 506 on Renal Function After Liver Transplantation 
J. McCauley, J. Fung, A. Jain. S. Todo. and T.E. Starzl 
FK S06 is a potent immunosuppressant agent which has 
undergone extensive in vitro and animal studies since 
its discovery in 1983. 1') Since the first International Work-
shop on FK S06 in 1987. growing excitement has sur-
rounded the development of an agent which is 100 times 
more potent than CyA. 1 The major limitation of CyA has 
been the almost universal development of nephrotoxicity, 
leading to renal failure and the need for dialysis in some 
patients.u The development of an agent which is more 
potent than Cy A and which is less nephrotoxic would be a 
major advance in organ transplantation. We report our 
preliminary results on renal function and associated fac-
tors, using FK S06 as the major immunosuppressant in 
humans after liver transplantation. 
PATIENTS AND METHODS 
The first human experience with FK 506 was obtained in patients 
who will hereafter be referred to as the "rescue" group. These 
were adult patients with significant Cy A toxicity. including 
chronic renal failure or hypertension. In addition to these compli-
cations, patients with coexisting pathologic evidence for rejection. 
which had been refractory to conventional methods. were in-
cluded in this group. A second group of patients ("primary") 
receiving orthotopic liver transplants were treated with FK 506 as 
the major immunosuppressant agent without prior exposure to 
CyA. 
FK 506 was initially administered intravenously (0.15 mg/kgld) 
for the first day. then switched to the oral form on the second day 
(0.3 mglkgld). FK 506 drug levels were monitored by immunoas-
say and CyA levels by radioimmunoassay.b In most patients, CyA 
was discontinued on the first day of FK 506 therapy. Daily routine 
laboratory data included blood sugar. electrolytes. blood urea 
nitrogen. serum creatinine (SCrl. complete blood cell count, and 
liver chemistries. 
The initial 20 primary treatment patients were retrospectively 
matched with 20 CyA-treated patients by liver disease, age, sex. 
and UNOS classification. These subjects were not matched for 
pretransplant renal function. The CyA-treated patients served as 
control subjects in comparisons of renal function and other 
associated variables. 
RESULTS 
Primary Treatment Group 
Since FK 506 and CyA-treated patients were not con-
trolled for renal function, pretransplant SCr was statisti-
cally different when all patients were considered. Serum 
creatinine was significantly greater in the CyA group at all 
times when compared with primary FK S06-treated pa-
tients (Fig 1). Three of the CyA group required hemodial-
ysis during the initial transplant admission. but none of the 
FK 506 group were dialyzed. 
An analysis of only patients with SCr < 1.S mg/dl is 
illustrated in Fig 2. This analysis included 17 FK 506 
patients and 12 CyA patients. Pretransplant SCr was less 
in CyA-treated patients (0.62 ± 0.24) compared with FK 
506 patients (0.74 ± .04 mg/dl), P = 0.08. Thereafter, SCr 
was significantly greater in the CyA-treated patients. Fur-
ther, all of the patients eventually requiring dialysis had 
SCr < 1.5 mg/dl. Acute renal failure requiring dialysis was 
associated with ischemic acute tubular necrosis in all 
cases. 
There was a poor correlation between SCr and FK 506 
levels (r = 0.45). FK 506 drug levels ranged from 0.2 to 8 
ng/m!. Decreasing drug dose and the associated drug level 
did not decrease SCr consistently. Conversely, CyA drug 
level and SCr were closely associated (r = 0.88). The Cy A 
drug levels ranged from 400 to 2.500 ng/m!. 
Hyperkalemia was a frequent occurrence in both CyA-
and FK 506-treated patients. In the FK 506 group, hyper-
kalemia was associated with low or low normal renin and 
aldosterone levels in all cases. In addition. hyperkalemic 
patients in both groups had higher SCr than normokalemic 
patients (Figs 3 and 4). The hyperkalemia was not severe 
and was responsive to ftudrocortisone acetate <0.1 to 0.2 
mg twice/d) in all cases requiring treatment. 
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Fig 1. Mean SCr (:!: SO) versus time in 20 primary FK 506 
patients and 20 CyA controls. 
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Fig 2. Mean SCr (:!: SO) versus time in 20 primary FK 506 and 
control CyA patients with pretransplant SCr < 1.5 mgJdl. 
Hypertension developed postoperatively in only one FK 
506-treated patient with Alagilles' syndrome and presumed 
renal artery stenosis. None of the remaining FK 506-
treated patients required antihypertensive therapy at any 
time. 
FK 506 as Primary Therapy For Uver Transplantation 
FK 506 as initial therapy for liver transplantation has 
revealed unprecedented results. The incidence of rejection 
has been reduced to very low levels. and prednisone doses 
have been drastically reduced. This will be discussed in 
detail by Dr Todo in his report on FK 506 as primary 
therapy for organ transplantation (in this issue). 
FK 506-Treated Rescue Group 
By definition. all of the rescue patients had CyA nephro-
toxicity prior to starting FK 506 therapy. Although mean 
SCr prior to FK 506 in liver transplant patients was 1.55 :!: 
1.3 mgldl. the range was 0.7 to 5.4 mgldl. Further. the 
mean glomerular filtration rate (GFR) as measured by 
iothalamate clearance was 35 :!: 16.9 cc/min. suggesting 
severely impaired renal function. None of these patients. 
however. was dialysis-dependent prior to FK 506 therapy. 
Renal function deteriorated in all rescue patients after 
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Fig 3. Mean SCr (:!: SEM) versus time in hyperkalemic and 
normokalemic pnmary FK 506-treated patients. 
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Fig 4. Mean SCr (:!: SO) versus time in hyperkalemic and 
normokalemic CyA-treated controls. 
starting FK 506 (Fig 5). This was associated with elevated 
eyA levels initially in most cases. but SCr remained 
elevated after CyA in the plasma became undetectable. 
Serum creatinine fell in many patients after 6 to 8 weeks of 
therapy. In many recently treated rescue patients not 
included in this analysis. FK 506 was initially given orally 
without prior intravenous therapy. This practice has atten· 
uatedthe later increase in SCr in most patients. 
Hyperkalemia occurred in all rescue patients at some 
time during therapy. However. all except two had been 
hyperkalemic during the 6 months prior to FK 506 therapy 
and while receiving CyA. Similar to the primary group, 
renin and aldosterone levels were low or low normal while 
these patients were hyperkalemic. Likewise. hyperkale-
mia was associated with increased SCr and was responsive 
to replacement therapy with ftudrocortisone acetate (Flor-
ineO. Florinef. in doses less than 0.2 mg twice/d. was 
usually ineffective in controlling the hyperkalemia. 
Hypertension requiring antihypertensive therapy was 
present in most of patients prior to FK 506 therapy (Fig 6). 
Some patients required as many as three antihypertensive 
agents to control blood pressure. In the 20 rescue patients. 
all antihypertensive agents were discontinued in the first 
week of FK 506 therapy due to an improvement in blood 
pressure. Three patients requiring three agents stopped all 
antihypertensives in the first week of FK 506 treatment. 
During weeks 2 to 3. the percentage of drug-free patients 
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Fig 5. Mean SCr (= SEM) versus time in rescue patients. 
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Fig 6. Percentage of rescue patients requiring antihypertensive 
agents versus time. 
decreased; this was associated with increasing SCr. By 
week 4. the percentage of drug-free patients had increased 
to approximately 85%. During weeks 2 to 3. one patient 
required an antihypertensive for the first time. but this was 
discontinued during week 4. There were no instances of 
new onset severe hypertension in any of the rescue pa-
tients. Subsequent experience with patients not included in 
this study has generally confirmed these observations in 
liver transplant patients. 
"Compassionate Rescue Patients" 
Four patients with refractory hepatic rejection who were 
dialysis-dependent. infected. required ventilatory support. 
and in intensive care units were treated with FK 506. 
These patients were termed "compassionate rescues" 
since many of them were not expected to survive given the 
severity and number of complications. FK 506 was initi-
ated with 0.15 mglkgld intravenously. and 0.3 mglkgld 
orally when the patients tolerated oral feedings. In one 
patient. urine output increased 24 hours after starting FK 
506 and discontinuing CyA. Renal function improved in 
the other patients within 2 weeks of starting therapy with 
FK 506. Hepatic rejection was completely reversed in all 
patients. and none of these previously critically ill patients 
died. 
One patient with CyA-induced hemolytic uremic syn-
drome was also treated with FK 506. This patient experi-
enced a prompt correction in hematologic parameters and 
improvement in renal function. This patient will be de-
scribed in detail in another communication. 
Efficacy in Treating Refractory Hepatic Rejection 
FK 506 reversed ongoing refractory hepatic rejection in 
the majority of cases. Many of these patients would have 
required retransplantation prior to FK 506 therapy. These 
remarkable results were accomplished without the use of 
high-dose steroids or OKT3. This will be discussed in 
detail by Dr Fung in his analysis of the results of FK 506 as 
rescue therapy. 
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DISCUSSION 
The first human trial of FK 506 has proven that it is a 
potent immunosuppressant with few side effects. This is 
contrary to early reports in animals. which suggested that 
it was a toxic agent causing vasculitis and failure to thrive 
in the majority of subjects.7 Subsequent human studies 
have not reproduced the severe toxicity noted in these 
studie!).8 
Based on our experience with human subjects. it ap-
pears that ( I) FK 506 is not a classic nephrotoxin leading to 
renal cell death and acute renal failure; (2) FK 506 does not 
have the pattern of nephrotoxicity found with CyA. but 
may have mild nephrotoxicity; and (3) prior exposure to 
CyA results in a consistent deterioration of renal function 
which may improve after weeks of therapy. 
In the first 20 patients treated with FK 506 alone. no 
cases of acute renal failure occurred during the first 4 
weeks or subsequently. This suggests that FK 506 is not an 
obvious renal cytotoxic agent. similar to aminoglycoside 
antibiotics or other nephrotoxins. Further. multiple urinal-
yses in both primary and rescue patients have not revealed 
findings suggesting subclinical acute tubular necrosis. 
Given the wide range of FK 506 drug levels. such a 
cytotoxic effect should have been uncovered at the higher 
drug levels. The modest rise in SCr noted in this study was 
not due to renal cell death. 
Previous reports of Cy A nephrotoxicity have disclosed a 
close association between drug level and SCr.s The 
changes in CyA dose were reflected in SCr within 24 
hours. With FK 506. a poor correlation exists between 
drug level and renal function. while CyA-induced acute 
renal failure has been described. usually associated with 
toxic drug levels. We have not noted this phenomenon 
with FK 506. FK 506 drug levels varied from 0.2 to 8 
nglm!. without associated changes in SCr. It is unlikely 
that changes in SCr will be a reliable marker of FK 506 
toxicity. 
Previous studies have suggested that Cy A. by increasing 
renal vascular tone. predisposes to toxic or ischemic acute 
renal failure. S The relatively high occurrence of acute renal 
failure in our Cy A control group and a previous study at 
this center support this observation.4 Conversely. the 
absence of acute renal failure in FK 506 patients suggests 
that it does not predispose to other causes of acute renal 
failure. In an earlier study. we noted a 90% mortality in 
liver transplant patients requiring dialysis. Reducing the 
incidence of acute renal failure and infection should reduce 
mortality in patients treated with FK 506. 
The effects of FK 506 on renal function are strikingly 
different in primary subjects when compared with rescue 
patients. Prior exposure to CyA and its resulting nephro-
toxicity has led to a predictable deterioration in renal 
function which improves after a period of weeks. The 
likely reason for this is the combined severe nephrotoxic-
ity of Cy A with the likely mild nephrotoxicity of FK 506. 
It is possible that renal tissue Cy A persists after plasma 
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drug levels have diminished. Nonetheless. the combined 
use of FK 506 and Cy A will be complicated by worsening 
renal function and should be avoided. In patients not 
suffering from chronic Cy A nephrotoxicity. renal function 
has been relatively well-preserved. When comparing pri-
mary therapy patients to their Cy A controls. FK 506 
appears to be significantly less nephrotoxic. Whether it 
causes less intrarenal vasoconstriction cannot be answered 
in this preliminary report. but ongoing studies in humans at 
this center will address this in later communications. In a 
previous study of dogs and rats conducted by Todo et al 
using an ischemic renal model. FK 506 was also found to 
be less nephrotoxic than CyA.'J Likewise. a study by 
Nelesnik et al (in this issue). has confirmed these findings. 
Hyperkalemia. which is usually mild. is a common 
occurrence with both Cy A and FK 506. Previous studies in 
CyA-treated patients have usually revealed hyporeninemic 
hypoaldosteronism. 10.11 This finding has also been noted in 
the FK 506-treated patients. The excellent response to 
mineralocorticoid replacement strongly supports this. In 
both Cy A- and FK 506-treated patients. an increase in SCr 
was also associated with hyperkalemia. suggesting that 
reduced excretion of potassium is due. in part. to a 
reduction in GFR. 
An unexpected finding in this study was the beneficial 
effect of FK 506 on CyA-induced hypertension. This 
suggests that FK 506 reduces the peripheral vascular 
resistance caused by CyA. Although a reduction in anti-
hypertensive medications was not universal. a dramatic 
elimination of hypertension occurred in some patients. 
This effect was unfortunately attenuated in the rescue 
patients by worsening renal function and presumed vol-
ume retention. It is likely that blood pressure control will 
also improve as renal function ameliorates with time. 
McCAULEY. FUNG. JAIN ET AL 
Although we have found no strong evidence that FK 506 
is as nephrotoxic as CyA. it is likely that FK 506 has a 
milder nephrotoxic effect. both early and after chronic 
exposure. More detailed studies of renal function are 
currently under way at the University of Pittsburgh. which 
will answer these questions in the future. 
In summary. FK 506 is a remarkably potent immuno-
suppressant agent which. at the very least. has less neph-
rotoxicity than Cy A after liver transplantation. Its ability 
to prevent rejection and to treat refractory rejection makes 
this an exciting and potentially revolutionary drug. More 
detailed studies. both in animals and humans. will more 
clearly define the influence of FK 506 on renal function. 
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